Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Gene Therapy for Choroideremia
NCT01461213Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Oct 2011
- Primary completion
- Oct 2017
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of timrepigene emparvovec in choroideremia, sponsored by University of Oxford. Started Oct 2011; status: completed.
02
Drugs
timrepigene emparvovec
03
Conditions
choroideremia
Beyond the preview
Go deeper on NCT01461213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01461213.